UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	$\boldsymbol{\cap}$	T	T	/	Ω	TZ
\mathbf{F}	u	Ж	ďΝ	/	8	-N

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 18, 2021

Tandem Diabetes Care, Inc.

(Exact name of registrant as specified in its charter)

20-4327508

001-36189

Delaware

of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Emerging growth company \square

Belaware		001 00100	=0 15=7500				
	(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)				
	11075 Roselle Street		92121				
	San Diego California (Address of principal executive offices)		(Zip Code)				
	Registrant's telep	ohone number, including area code	: (858) 366-6900				
	N/A (Former name or former address, if changed since last report)						
Chec	ck the appropriate box below if the Form 8-K filing is intended to	simultaneously satisfy the filing obl	igation of the registrant under any of the following provisions:				
	☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)						
	□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)						
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))						
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))						
Securities registered pursuant to Section 12(b) of the Act:							
	<u>Title of Each Class</u> Common Stock, par value \$0.001 per share	Symbol TNDM	Name of Exchange on Which Registered Nasdaq Global Market				

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 18, 2021, Tandem Diabetes Care, Inc. (the "Company") held a virtual Annual Meeting of Stockholders (the "Annual Meeting"). There were 62,555,485 shares of the Company's common stock ("Common Stock") outstanding on March 23, 2021, the record date for the Annual Meeting. At the Annual Meeting, 55,473,103 shares of Common Stock were present virtually or represented by proxy.

The following tables set forth the final results of the voting for the matters voted upon at the Annual Meeting. These matters are described in more detail in the Company's definitive proxy statement, filed with the Securities and Exchange Commission (the "SEC") on April 7, 2021 (the "Proxy Statement").

Proposal 1: The election of three Class II directors to serve a three-year term to expire at the 2024 annual meeting of stockholders. The stockholders elected the three Class II directors by the following votes:

Name of Director	For	Against	Abstain	Broker Non-Votes
Dick P. Allen	41,972,599	7,715,670	33,718	5,751,116
Rebecca B. Robertson	48,918,233	771,448	32,306	5,751,116
Rajwant S. Sodhi	49,410,769	275,666	35,552	5,751,116

<u>Proposal 2</u>: The ratification of the appointment of Ernst & Young LLP to serve as the Company's independent registered public accountant for the year ending December 31, 2021. The proposal received the following votes:

For	Against	Abstain	Broker Non-Votes
53,766,641	1,668,487	37,975	0

Proposal 3: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement. The proposal received the following votes:

For	Against	Abstain	Broker Non-Votes
43,453,674	6,206,486	61,827	5,751,116

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Tandem Diabetes Care, Inc.

By: /s/ David B. Berger

David B. Berger

Executive Vice President, Chief Business Operations & Compliance Officer

Date: May 19, 2021